证券代码：600628 证券简称：新世界 公告编号：临2025-019 上海新世界股份有限公司 2025年半年度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号—行业信息披露》附件《第四号 —零售》、《关于做好主板上市公司 2025 年半年度报告披露工作的重要提醒》等有关规定的 要求，上海新世界股份有限公司（以下简称"公司"）现将 2025 年半年度主要经营数据披 露如下： 一、2025 年半年度，公司无门店变动情况； 二、2025 年半年度，公司无拟增加门店情况； 三、2025 年半年度主要经营数据： 上海新世界股份有限公司 董事会 二零二五年八月二十九日 | 业态 | 经营模式 | 2025 年 1-6 | 月（单位：万元） | | 2024 年 1-6 | 月（单位：万元） | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 营业收入 | 营业成本 | 毛利率% | 营业收入 | 营业成本 ...

Group 1 - The core business of the company is the research, production, and sales of rehabilitation medical devices, with a wide range of products across 10 categories and over 1,000 products [2] - The company has received multiple awards for its projects, including first prizes for various rehabilitation technology initiatives from different medical and scientific associations [2] - As of the first quarter of 2025, the company reported a revenue of 186 million yuan, a year-on-year increase of 10.02%, while net profit decreased by 41.26% to 22.95 million yuan [3] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 109.54, significantly higher than the industry average of 59.32 and the median of 39.97 [3] - The total market capitalization of the company is 9.51 billion yuan [3] - As of the first quarter of 2025, six institutions hold shares in the company, with a total of 634,800 shares valued at 2.8 million yuan [1]

Core Viewpoint - The company, Xiangyu Medical, is experiencing a decline in stock price and has a high price-to-earnings (PE) ratio compared to its industry peers, indicating potential overvaluation in the market [1][3]. Group 1: Company Performance - As of the latest quarterly report for Q1 2025, the company achieved a revenue of 186 million yuan, representing a year-on-year increase of 10.02% [3]. - The net profit for the same period was 22.95 million yuan, showing a significant decline of 41.26% year-on-year [3]. - The gross profit margin stands at 65.30%, indicating a strong profitability despite the drop in net profit [3]. Group 2: Market Position - The current stock price of Xiangyu Medical is 57.45 yuan, with a rolling PE ratio of 105.87 times, which is significantly higher than the industry average of 55.70 times and the industry median of 39.08 times [1][3]. - The total market capitalization of the company is approximately 9.192 billion yuan [1]. Group 3: Industry Recognition - The company has received multiple awards for its projects, including the first prize from the Chinese Rehabilitation Medicine Association for its project on chronic musculoskeletal diseases [2]. - Other notable awards include the first prize for the high-performance non-invasive brain-machine interface technology from Tianjin and various other provincial and national recognitions for its innovative rehabilitation technologies [2].

Core Viewpoint - Xiangyu Medical's stock closed at 44.97 yuan, down 2.24%, with a rolling PE ratio of 82.87 times, indicating a high valuation compared to the industry average [1][3]. Company Overview - Xiangyu Medical specializes in the research, production, and sales of rehabilitation medical devices, offering over a thousand products across ten categories, including rehabilitation therapy, training, and assessment [2]. - The company has received multiple awards for its projects, including first prizes for various rehabilitation technology initiatives from different medical and scientific associations [2]. Financial Performance - In the first quarter of 2025, the company reported revenue of 186 million yuan, a year-on-year increase of 10.02%, while net profit was 22.95 million yuan, reflecting a decline of 41.26% [3]. - The gross profit margin for the company stood at 65.30% [3]. Market Position - Xiangyu Medical's PE ratio of 82.87 times is significantly higher than the industry average of 53.65 times and the median of 37.22 times, placing it at the 102nd position in the industry ranking [1][3]. - As of March 31, 2025, the number of shareholders increased to 5,895, with an average holding value of 352,800 yuan per shareholder [1].

Group 1 - The core business of the company is the research, production, and sales of rehabilitation medical devices, with a wide range of products across 10 categories and over 1,000 types [2] - The company has received multiple awards for its projects, including first prizes from the Chinese Rehabilitation Medicine Association and various provincial awards for technological advancements in rehabilitation solutions [2] - As of March 31, 2025, the company had 5,895 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Group 2 - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 186 million yuan, representing a year-on-year increase of 10.02%, while net profit decreased by 41.26% to 22.95 million yuan, with a gross margin of 65.30% [3] - The company's rolling price-to-earnings (PE) ratio is 80.39, significantly higher than the industry average of 51.29 and the median of 37.02, ranking it 101st in the industry [1][3] - The company operates in the medical device industry, which has an average PE ratio of 51.29 and a median of 37.02, indicating a relatively high valuation compared to its peers [1][3]